tizanidine has been researched along with Spinal Cord Injuries in 18 studies
tizanidine: RN given refers to parent cpd; structure
tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
Spinal Cord Injuries: Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity." | 8.84 | Update on tizanidine for muscle spasticity and emerging indications. ( Garay, E; Malanga, G; Reiter, RD, 2008) |
| "Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI)." | 8.84 | A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. ( Henney, HR; Kamen, L; Runyan, JD, 2008) |
| "Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity." | 4.84 | Update on tizanidine for muscle spasticity and emerging indications. ( Garay, E; Malanga, G; Reiter, RD, 2008) |
| "Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI)." | 4.84 | A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. ( Henney, HR; Kamen, L; Runyan, JD, 2008) |
| "The efficiency and duration of action of a single oral dose (8 mg) of tizanidine in patients with spinal cord injuries were determined by studying its antispastic, cardiovascular and sedative effects along with its pharmacokinetic profile in five tetraplegic and five paraplegic patients." | 3.67 | Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. ( Baker, H; Desai, P; el Masri, W; Frankel, HL; Luckitt, J; Mathias, CJ, 1989) |
| "Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d." | 2.67 | Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. ( Bugaresti, J; Martinez-Arizala, A; Nance, PW; Shellenberger, K; Sheremata, W, 1994) |
| "With the introduction of the antispasticity agent, tizanidine hydrochloride (Zanaflex), physicians have requested information about the optimal way to switch appropriate patients from baclofen to tizanidine." | 2.40 | An approach to switching patients from baclofen to tizanidine. ( Brenner, R; Hyman, N; Knobler, R; O'Brien, M; Stephan, T, 1998) |
| "Tizanidine (2mg) was administered (4\\day), for 4 weeks." | 1.42 | Comparison between the therapeutic effects of robotic-assisted locomotor training and an anti-spastic medication on spasticity. ( Mirbagheri, MM, 2015) |
| "It provides effective reduction of spasticity without affecting muscle strength." | 1.30 | Spasticity: current and future management. Royal College of Physicians, November 13, 1997. ( , 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.56) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mirbagheri, MM | 7 |
| Kindig, M | 1 |
| Niu, X | 2 |
| Varoqui, D | 1 |
| Chu, VW | 1 |
| Hornby, TG | 1 |
| Schmit, BD | 1 |
| Duffell, LD | 4 |
| Brown, GL | 3 |
| Brown, G | 1 |
| Malanga, G | 1 |
| Reiter, RD | 1 |
| Garay, E | 1 |
| Chen, D | 1 |
| Rymer, WZ | 1 |
| Taricco, M | 2 |
| Pagliacci, MC | 1 |
| Telaro, E | 2 |
| Adone, R | 2 |
| Kamen, L | 1 |
| Henney, HR | 1 |
| Runyan, JD | 1 |
| Nance, PW | 1 |
| Bugaresti, J | 1 |
| Shellenberger, K | 1 |
| Sheremata, W | 1 |
| Martinez-Arizala, A | 1 |
| Brenner, R | 1 |
| Hyman, N | 1 |
| Knobler, R | 1 |
| O'Brien, M | 1 |
| Stephan, T | 1 |
| Pagliacci, C | 1 |
| Honda, M | 1 |
| Sekiguchi, Y | 1 |
| Sato, N | 1 |
| Ono, H | 1 |
| Mathias, CJ | 1 |
| Luckitt, J | 1 |
| Desai, P | 1 |
| Baker, H | 1 |
| el Masri, W | 1 |
| Frankel, HL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595] | 36 participants (Anticipated) | Interventional | 2023-05-18 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for tizanidine and Spinal Cord Injuries
| Article | Year |
|---|---|
Update on tizanidine for muscle spasticity and emerging indications.
Topics: Adrenergic alpha-2 Receptor Agonists; Clonidine; Dose-Response Relationship, Drug; Humans; Low Back | 2008 |
Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
Topics: Baclofen; Clonidine; Dantrolene; Humans; Muscle Relaxants, Central; Muscle Spasticity; Randomized Co | 2006 |
A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Topics: Brain Injuries; Clonidine; Disease Progression; Drug Interactions; Female; Humans; Middle Aged; Mult | 2008 |
An approach to switching patients from baclofen to tizanidine.
Topics: Baclofen; Clinical Competence; Clonidine; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Mus | 1998 |
Pharmacological interventions for spasticity following spinal cord injury.
Topics: Baclofen; Clonidine; Dantrolene; Humans; Muscle Relaxants, Central; Parasympatholytics; Spasm; Spina | 2000 |
5 trials available for tizanidine and Spinal Cord Injuries
| Article | Year |
|---|---|
Effect of antispastic drugs on motor reflexes and voluntary muscle contraction in incomplete spinal cord injury.
Topics: Adult; Baclofen; Clonidine; Cross-Over Studies; Double-Blind Method; Electromyography; Humans; Isome | 2014 |
Interventions to Reduce Spasticity and Improve Function in People With Chronic Incomplete Spinal Cord Injury: Distinctions Revealed by Different Analytical Methods.
Topics: Analysis of Variance; Cervical Vertebrae; Chronic Disease; Clonidine; Data Interpretation, Statistic | 2015 |
Variability in responsiveness to interventions in people with spinal cord injury: Do some respond better than others?
Topics: Ankle Joint; Clonidine; Humans; Muscle Relaxants, Central; Muscle Spasticity; Spinal Cord Injuries; | 2014 |
Classifying and predicting endurance outcomes of α2-adrenergic agonist intervention in spinal cord injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Clonidine; Humans; Physical Endurance; Recovery of Function; S | 2014 |
Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Adult; Aged; Clonidine; Female; Humans | 1994 |
8 other studies available for tizanidine and Spinal Cord Injuries
| Article | Year |
|---|---|
Therapeutic effects of anti-spastic medication on neuromuscular abnormalities in SCI: a system identification approach.
Topics: Algorithms; Ankle; Ankle Joint; Anticonvulsants; Clonidine; Electromyography; Exercise Therapy; Huma | 2013 |
Facilitatory effects of anti-spastic medication on robotic locomotor training in people with chronic incomplete spinal cord injury.
Topics: Adult; Aged; Biomechanical Phenomena; Clonidine; Female; Gait; Humans; Isometric Contraction; Learni | 2015 |
Comparison between the therapeutic effects of robotic-assisted locomotor training and an anti-spastic medication on spasticity.
Topics: Ankle Joint; Clonidine; Electromyography; Humans; Motor Activity; Muscle Relaxants, Central; Muscle | 2015 |
Quantification of the effects of an alpha-2 adrenergic agonist on reflex properties in spinal cord injury using a system identification technique.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adult; Ankle Joint; Clonidine; Elas | 2010 |
A new drug to treat spasticity?
Topics: Clonidine; Drug Approval; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Spinal Cord Injurie | 1996 |
Spasticity: current and future management. Royal College of Physicians, November 13, 1997.
Topics: Clinical Trials as Topic; Clonidine; Dose-Response Relationship, Drug; Gait; Humans; Muscle Spastici | 1998 |
Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine.
Topics: Animals; Cervical Vertebrae; Clonidine; Imidazoline Receptors; Male; Muscle Relaxants, Central; Rats | 2002 |
Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.
Topics: Administration, Oral; Adult; Blood Pressure; Clonidine; Drug Evaluation; Heart Rate; Humans; Male; M | 1989 |